Variable association of complement activation by rituximab and paclitaxel in cancer patients in vivo and in their screening serum in vitro with clinical manifestations of hypersensitivity: A pilot study

European Journal of Nanomedicine

Volumn 7, Issue 4, 2015, Pages 289-301

  Kozma, Gergely Tibor ^a,b   Meszaros, Tamas ^a,b   Weiszhar, Zsoka ^a,b   Schneider, Tamas ^c   Rosta, Andras ^c   Urbanics, Rudolf ^a,b   Rosivall, Laszlo ^a,b   Szebeni, Janos ^a,b,d  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b SeroScience Ltd   (Hungary)

^c Department of Gastroenterology and Endoscopy   (Hungary)

^d UNIVERSITY OF MISKOLC   (Hungary)

Author keywords

Anaphylaxis; anti drug antibodies; cancer therapy; hypersensitivity reactions; immunogenicity; nanomedicines

Indexed keywords

CHEMICAL ACTIVATION; DISEASES; DRUG PRODUCTS; DRUG THERAPY; MEDICAL NANOTECHNOLOGY; MONOCLONAL ANTIBODIES; SCREENING;

ANAPHYLAXIS; ANTICANCER DRUG; CANCER THERAPY; CLINICAL MANIFESTATION; COMPLEMENT ACTIVATIONS; HYPERSENSITIVITY REACTION; IMMUNOGENICITY; RATE LIMITING FACTORS;

DIAGNOSIS;

COMPLEMENT; DOCETAXEL; INFUSION FLUID; PACLITAXEL; RITUXIMAB; TRASTUZUMAB;

BLOOD SAMPLING; BRADYCARDIA; BURNING SENSATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; DIZZINESS; DRUG HYPERSENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPERTENSION; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; NAUSEA; PILOT STUDY; REVIEW; SCREENING; SERUM; XEROSTOMIA;

EID: 84947424701     PISSN: 16625986     EISSN: 1662596X     Source Type: Journal    
DOI: 10.1515/ejnm-2015-0026     Document Type: Review

References (54)

1. Pichler WJ. Adverse side-effects to biological agents. Allergy 2006;61:912-20.
2. Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008;122:574-80.
3. Castells MC. Hypersensitivity to antineoplastic agents. Curr Pharm Des 2008;14:2892-901.
4. Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010;65:657-61.
5. Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol 2011;7:55-63.
6. Szebeni J. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol Immunol 2014;61:163-73.
7. Szebeni J, Fontana JL, Wassef NM, Mongan PD, Morse DS, Dobbins DE, et al. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 1999;99:2302-9.
8. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced immune toxicity. Toxicology 2005;216: 106-21.
9. Szebeni J. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs and radiocontrast agents. Crit Rev Ther Drug Carr Syst 2001;18:567-606.
10. Szebeni J. Complement activation-related pseudoallergy: mechanism of anaphylactoid reactions to drug carriers and radiocontrast agents. In: Szebeni J, editor. The complement system: novel roles in health and disease. Boston: Kluwer, 2004:399-440.
11. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003;98:1315-24.
12. Duburque C, Lelong J, Iacob R, Seddik M, Desreumaux P, Fournier C, et al. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. Aliment Pharmacol Ther 2006;24:851-8.
13. Kang SP, Saif MW. Infusion-Related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer: Iidentification, prevention and management. J Support Oncol 2007;5:451-7.
14. Brennan PJ, Rodriguez BT, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 2009;124:1259-66.
15. Vultaggio A, Maggi E, Matucci A. Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Curr Opin Allergy Clin Immunol 2011;11:262-8.
16. Hong DI, Bankova L, Cahill KN, Kyin T, Castells MC. Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies. Expert Rev Clin Immunol 2012;8:43-52.
17. Sharma D, Chelvi TP, Kaur J, Chakravorty K, De TK, Maitra A, et al. Novel Taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated Taxol for drug delivery in cancer therapy. Oncol Res 1996;8:281-6.
18. Preston NJ. Paclitaxel (Taxol)-a guide to administration. Eur J Cancer Care (Engl) 1996;5:147-52.
19. Paul DM, Garrett AM, Meshad M, DeVore RD, Porter LL, Johnson DH. Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience. Semin Oncol 1996;23(1 Suppl 1): 48-52.
20. Hajek R, Vorlicek J, Slavik M. Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview. Neoplasma 1996;43:141-54.
21. Hajek R. [Paclitaxel (Taxol)]. Cas Lek Cesk 1996;135:393-6.
22. Blom R, Palm N, Simonsen E. Paclitaxel (Taxol) monotherapy in the treatment of progressive and recurrent ovarian carcinoma after platinum-based chemotherapy. Acta Oncol 1996;35:733-6.
23. Piccart MJ, Gore M, Ten Bokkel Huinink W, Van Oosterom A, Verweij J, Wanders J, et al. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer I 1995;87:676-81.
24. Fumoleau P, Perrocheau G, Maugard-Louboutin C, Lemevel B. [Paclitaxel (Taxol) and docetaxel (Taxotere): results of phase II trials in monochemotherapy]. Bull Cancer 1995;82:629-36.
25. Francis PA, Kris MG, Rigas JR, Grant SC, Miller VA. Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer. Lung Cancer 1995;12(Suppl 1):S163-72.
26. Uziely B, Jeffers S, Muggia F. Low doses of dexamethasone protect against paclitaxel (Taxol)-related hypersensitivity reactions following cycle 1. Ann Oncol 1994;5:474.
27. Greco FA, Hainsworth JD. Paclitaxel (Taxol): phase I/II trial comparing 1-hour infusion schedules. Semin Oncol 1994; 21(5 Suppl 8):3-8.
28. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Seminars in Oncology 1993;20(4 Suppl 3):1-15.
29. Peereboom DM, Donehower RC, Eisenhauer EA, McGuire WP, Onetto N, Hubbard JL, et al. Successful re-treatment with taxol after major hypersensitivity reactions. J Clin Oncol 1993;11:885-90.
30. Onetto N, Canetta R, Winograd B, Catane R, Dougan M, Grechko J, et al. Overview of Taxol safety. J Natl Cancer Inst Monogr 1993:131-9.
31. Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, et al. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 1991;9:1261-7.
32. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from Taxol. J Clin Oncol 1990;8:1263-8.
33. Weiss RB, Baker JR. Hypersensitivity reactions from antineoplastic agents. Cancer Metastasis Rev 1987;6:413-32.
34. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. J Am Med Assoc 1998;279:1200-5.
35. Adkinson NF, Essayan D, Gruchalla R, Haggerty H, Kawabata T, Sandler JD, et al. Task force report: future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions. J Allergy Clin Immunol 2002;109:S461-78.
36. Szebeni J. Hemocompatibility testing for nanomedicines and biologicals: predictive assays for complement mediated infusion reactions. Eur J Nanomed 2012;5:33-53.
37. Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer I 1998;90:300-6.
38. Szebeni J, Baranyi L, Savay S, Gze O, Alving CR, Bger R, et al. Complement activation during hemorrhagic shock and resuscitation in swine. Shock 2003;20:347-55.
39. Weiszh Z, Czz J, Rz C, Rosivall L, Szebeni J, Rozsnyay Z. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. Eur J Pharm 2012;45:492-8.
40. Chanan-Khan A, Szebeni J, Savay S, Liebes L, Rafique NM, Alving CR, et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol 2003;14:1430-7.
41. Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 2004;114:371-6.
42. Van Beers MM, Bardor M. Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins. Biotechnol J 2012;7:1473-84.
43. Szebeni J, Jiskoot W. Immunological issues with nanomedicines: immunogenicity, hypersensitivity, accelerated clearance and immune suppression. In: Torchillin V, editor. Handbook of nanobiomedical research. Singapore: World Scientific, 2014:45-73.
44. Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 1993;19:351-86.
45. Tsavaris NB, Kosmas C. Risk of severe acute hypersensitivity reactions after rapid paclitaxel infusion of less than 1-h duration. Cancer Chemoth Pharm 1998;42:509-11.
46. Szebeni J, Alving CR, Savay S, Barenholz Y, Priev A, Danino D, et al. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Int Immunopharmacol 2001;1:721-35.
47. van der Kolk LE, Grillo-Lez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Brit J Haematol 2001;115:807-11.
48. Szebeni J, Muggia F, Gabizon A, Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipientbased therapeutic products: prediction and prevention. Adv Drug Deliver Rev 2011;63:1020-30.
49. Szebeni J, Baranyi B, Savay S, Lutz LU, Jelezarova E, Bunger R, et al. The role of complement activation in hypersensitivity to pegylated liposomal doxorubicin (Doxil). J Lipos Res 2000;10:347-61.
50. Zhou Z, Yang R. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura. Cr Rev Oncol-Hem 2008;65:21-31.
51. Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease-the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007;3:86-95.
52. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007;44:3823-37.
53. Mollnes TE, Brekke OL, Fung M, Fure H, Christiansen D, Bergseth G, et al. Essential role of the C5a receptor in E coliinduced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002;100:1869-77.
54. Bexborn F, Engberg AE, Sandholm K, Mollnes TE, Hong J, Nilsson Ekdahl K. Hirudin versus heparin for use in whole blood in vitro biocompatibility models. J Biomed Mater Res A 2009;89:951-9.